Table of Contents Author Guidelines Submit a Manuscript
Stroke Research and Treatment
Volume 2017, Article ID 7365684, 13 pages
https://doi.org/10.1155/2017/7365684
Clinical Study

Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack

1Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Nottingham NG5 1PB, UK
2Stroke, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK
3Platelet Solutions Ltd., Division of Clinical Neuroscience, University of Nottingham, Queen’s Medical Centre Campus, Nottingham NG7 2UH, UK
4Platelet Research Group/Stroke, Division of Clinical Neuroscience, University of Nottingham, Queen’s Medical Centre Campus, Nottingham NG7 2UH, UK
5Vascular Medicine, Division of Medical Sciences and GEM, School of Medicine, University of Nottingham, Nottingham, UK
6Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK
7University of Nottingham, Nottingham, UK

Correspondence should be addressed to Philip M. Bath; ku.ca.mahgnitton@htab.pilihp

Received 8 December 2016; Revised 3 March 2017; Accepted 30 March 2017; Published 24 May 2017

Academic Editor: Chelsea Kidwell

Copyright © 2017 Philip M. Bath et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. R. Lees, P. M. W. Bath, and A. R. Naylor, “ABC of arterial and venous disease. Secondary prevention of transient ischaemic attack and stroke,” British Medical Journal, vol. 320, pp. 991–994, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Rashid, J. Leonardi-Bee, and P. Bath, “Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review,” Stroke, vol. 34, no. 11, pp. 2741–2748, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Amarenco, J. Bogousslavsky, A. Callahan et al., “High-Dose Atorvastatin after Stroke or Transient Ischemic Attack,” The New England Journal of Medicine, vol. 355, pp. 549–559, 2006. View at Publisher · View at Google Scholar
  4. EAFT (European Atrial Fibrillation Trial) Study Group, “Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke,” The Lancet, vol. 342, no. 8882, pp. 1255–1262, 1993. View at Google Scholar · View at Scopus
  5. H. C. Diener, R. L. Sacco, S. Yusuf et al., “Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the prevention regimen for effectively avoiding second strokes (profess) trial: a double-blind, active and placebo-controlled study,” Lancet Neurol, vol. 7, pp. 875–884, 2008. View at Google Scholar
  6. Royal College of Physicians, National clinical guideline for stroke, 4th edition, 2012.
  7. “Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients,” British Medical Journal, vol. 324, pp. 71–86, 2002. View at Publisher · View at Google Scholar
  8. M. Gent, D. Beaumont, J. Blanchard, M. G. Bousser et al., “A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie),” Lancet, vol. 384, pp. 1329–1339, 1996. View at Google Scholar
  9. H. C. Diener, L. Cunha, C. Forbes, J. Sivenius, P. Smets, and A. Lowenthal, “European stroke prevention study 2. dipyridamole and acetylsalicylic acid in the secondary prevention of stroke,” Journal of the Neurological Sciences, vol. 143, no. 1-2, pp. 1–13, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. PH. Halkes, J. van Gijn, LJ. Kappelle, PJ. Koudstaal, and A. Algra, “Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (esprit): Randomised controlled trial,” Lancet, vol. 367, pp. 1665–1673, 2006. View at Google Scholar
  11. J. Leonardi-Bee, P. M. W. Bath, M.-G. Bousser et al., “Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials,” Stroke, vol. 36, no. 1, pp. 162–168, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. H. A. Halkes, L. J. Gray, P. M. W. Bath et al., “Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 11, pp. 1218–1223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. R. L. Sacco, H. C. Diener, S. Yusuf et al., “Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke,” the New England Journal of Medicine, vol. 359, pp. 1238–1251, 2008. View at Google Scholar
  14. NICE, Clopidogrel and modified release dipyridamole for the prevention of occlusive vascular events. 2010.
  15. Intercollegiate Stroke Working Party, National clinical guideline for stroke, 4th edition, 2012.
  16. M. Cattaneo, “Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 1980–1987, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. P. A. Gurbel, K. P. Bliden, B. L. Hiatt, and C. M. O'Connor, “Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity,” Circulation, vol. 107, no. 23, pp. 2908–2913, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Tendera and W. Wojakowski, “Role of antiplatelet drugs in the prevention of cardiovascular events,” Thrombosis Research, vol. 110, no. 5-6, pp. 355–359, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Heptinstall, J. R. Glenn, J. A. May, R. F. Storey, and R. G. Wilcox, “Clopidogrel resistance,” Catheterization and Cardiovascular Interventions, vol. 63, no. 3, pp. 397-398, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Fontana, S. Nolli, G. Reber, and P. de Moerloose, “Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers,” Journal of Thrombosis and Haemostasis, vol. 4, no. 4, pp. 813–819, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. A. D. Michelson, M. D. Linden, M. I. Furman et al., “Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance',” Journal of Thrombosis and Haemostasis, vol. 5, no. 1, pp. 75–81, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Serebruany, G. Cherala, C. Williams et al., “Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of 'resistance',” American Heart Journal, vol. 158, no. 6, pp. 925–932, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. R. F. Storey, “Clopidogrel in acute coronary syndrome: to genotype or not?” The Lancet, vol. 373, no. 9660, pp. 276–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. J. Vlachojannis, G. Dimitropoulos, and D. Alexopoulos, “Clopidogrel resistance: current aspects and future directions,” Hellenic Journal of Cardiology, vol. 52, no. 3, pp. 236–245, 2011. View at Google Scholar · View at Scopus
  25. J. M. Siller-Matula, D. Trenk, K. Schrör et al., “Response variability to P2Y12 receptor inhibitors: expectations and reality,” JACC: Cardiovascular Interventions, vol. 6, no. 11, pp. 1111–1128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. R. FitzGerald and M. Pirmohamed, “Aspirin resistance: effect of clinical, biochemical and genetic factors,” Pharmacology and Therapeutics, vol. 130, no. 2, pp. 213–225, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. G. S. Mannu, A. Macartney, J. R. A. Lambert et al., “The clinical utility of multiplate analyser measurement in platelet function testing following stroke and transient ischaemic attack,” European Journal of Haematology, vol. 94, no. 2, pp. 138–144, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Zhao, S. Fletcher, C. Weaver et al., “Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke,” Thrombosis and Haemostasis, vol. 93, no. 3, pp. 527–534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Harrison, H. Segal, K. Blasbery, C. Furtado, L. Silver, and P. M. Rothwell, “Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry,” Stroke, vol. 36, no. 5, pp. 1001–1005, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Harrison, H. Segal, L. Silver, A. Syed, F. C. Cuthbertson, and P. M. Rothwell, “Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests,” Platelets, vol. 19, no. 2, pp. 119–124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. S. C. Fox, J. A. May, A. Shah, U. Neubert, and S. Heptinstall, “Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin,” Platelets, vol. 20, no. 4, pp. 250–259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Heptinstall, S. Fox, J. May, A. White, and N. Dovlatova, “A fixative developed to enable remote platelet function testing: uses and applications,” Current Topics in Pharmacology, vol. 19, pp. 1–12, 2015. View at Google Scholar
  33. M. R. Thomas, Y. D. Wijeyeratne, J. A. May, A. Johnson, S. Heptinstall, and S. C. Fox, “A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel,” Platelets, vol. 25, no. 8, pp. 612–618, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. The TARDIS Trial Investigators, “Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388),” International Journal of Stroke, vol. 10, no. 7, pp. 1159–1165, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Bath, K. Robson, L. J. Woodhouse, N. Sprigg, R. Dineen, and S. Pocock, “Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial,” International Journal of Stroke, vol. 10, no. 3, pp. 449–451, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. P. M. W. Bath, A. Blann, N. Smith, and R. J. Butterworth, “Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome,” Platelets, vol. 9, no. 3-4, pp. 155–159, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Fox, J. May, A. Johnson et al., “Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers,” Platelets, vol. 24, no. 5, pp. 392–400, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Heptinstall, S. Fox, J. Crawford, and M. Hawkins, “Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin,” Thrombosis Research, vol. 42, no. 2, pp. 215–223, 1986. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Tobin, J. Kinsella, D. Collins et al., “Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study,” British Journal of Haematology, vol. 152, no. 5, pp. 640–647, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Wang, X. Zhao, J. Lin et al., “Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack,” Journal of the American Medical Association, vol. 316, no. 1, pp. 70–78, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Pan, W. Chen, Y. Xu et al., “Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis,” Circulation, vol. 135, pp. 21–33, 2017. View at Google Scholar
  42. G. G. Duthie and A. D. Wood, “Natural salicylates: foods, functions and disease prevention,” Food and Function, vol. 2, no. 9, pp. 515–520, 2011. View at Publisher · View at Google Scholar · View at Scopus